Acepodia Biotech, Inc.

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Acepodia is a privately held US-Taiwan biotechnology company committed to developing safe, effective, and affordable immunotherapeutic medicines targeting diseases with significant unmet medical needs, with a primary focus on oncology. Acepodia’s proprietary ACC (Antibody Cell-Conjugation) technology platform links tumor targeting antibodies to the surface of a novel and proprietary human NK cell line that have been specifically selected for their potent antitumor activity. The ACC technology can be seamlessly combined with currently available antibodies allowing for the rapid development of new targeted therapies in multiple indications, without the need for genetic engineering.
Several off-the-shelf allogeneic cell therapies in Acepodia pipeline are developing for both solid and hematological malignancies, including the lead HER2 targeting drug candidate, ACE1702. The phase 1 study of ACE1702 for patients with HER2 positive solid tumors is ongoing now in US.
Company Type:
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
ACE1702
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO and President
Acepodia Biotech, Inc.